Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0187)
Name
Cannabinol
Synonyms
cannabinol; 521-35-7; Cannabinolo [DCIT]; Cannabinolum [INN-Latin]; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo(b,d)pyran; 6H-Dibenzo(b,d)pyran-1-ol, 6,6,9-trimethyl-3-pentyl-; 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol; NSC 134455; 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol; 7UYP6MC9GH; NSC-134455; CHEMBL74415; CHEBI:3360; DTXSID3048996; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl-; NCGC00168261-01; Cannabinolo; Cannabinolum; Cannabinol [INN:BAN]; Cannabinol (CBN); UNII-7UYP6MC9GH; BRN 0237145; Cannabinol; 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; CBN; NSC 134455; Cannabinoids; Cannabinol (6CI); CANNABINOL [MI]; CANNABINOL [INN]; CANNABINOL [WHO-DD]; GTPL740; 5-17-04-00567 (Beilstein Handbook Reference); DivK1c_000972; SCHEMBL121085; Cannabinol, analytical standard; Cannabinol, 1mg/ml in Methanol; DTXCID3028922; HMS503C05; KBio1_000972; NINDS_000972; Cannabinol 1.0 mg/ml in Methanol; Tox21_113486; BDBM50061117; LMPK13120002; NSC134455; AKOS024457448; DB14737; IDI1_000972; CAS-521-35-7; 6H-Dibenzo[b, 6,6,9-trimethyl-3-pentyl-; Cannabinol (CBN) 100 microg/mL in Methanol; C07580; Cannabinol (CBN) 1000 microg/mL in Methanol; Cannabinol (CBN) 250 microg/mL in Acetonitrile; EN300-7456337; A934070; L000158; Q265831; WLN: T B666 HO IHJ CQ E5 I1 I1 M1; 6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; 3-Amyl-1-hydroxy-6,9-trimethyl-6H-dibenzo[b,d]pyran; 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol #; Cannabinoids Mixture 187 100 microg/mL in Acetonitrile; Cannabinoids Mixture 188 500 microg/mL in Acetonitrile; Z2680631269; Cannabinoids Mixture 189 1000 microg/mL in Acetonitrile; Cannabinoids Mixture 201 1000 microg/mL in Acetonitrile; 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol(Cannabinol); 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol (Cannabinol); 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl- (7CI,8CI,9CI)

    Click to Show/Hide
Status
Investigative
Drug Type
Small molecular drug
Structure
Formula
C21H26O2
IUPAC Name
6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol
Canonical SMILES
CCCCCC1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)C)(C)C)O
InChI
InChI=1S/C21H26O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h9-13,22H,5-8H2,1-4H3
InChIKey
VBGLYOIFKLUMQG-UHFFFAOYSA-N
PubChem CID
2543
TTD Drug ID
D0U5LL
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Nervous system disease ICD-11: 8E7Z
 Disease Info 
Pathway Response Ferroptosis hsa04216
Calcium signaling pathway hsa04020
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model HT22 cells Normal Mus musculus CVCL_0321
SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
BV-2 cells Normal Mus musculus CVCL_0182
Response regulation Cannabinol directly targets mitochondria and preserves key mitochondrial functions including redox regulation, calcium uptake, membrane potential, bioenergetics, biogenesis, and modulation of fusion/fission dynamics that are disrupted following induction of oxytosis/ferroptosis. Oxytosis/ferroptosis recapitulates several aspects of mitochondrial pathology that are relevant to neurodegenerative diseases.
References
Ref 1 Cannabinol inhibits oxytosis/ferroptosis by directly targeting mitochondria independently of cannabinoid receptors. Free Radic Biol Med. 2022 Feb 20;180:33-51. doi: 10.1016/j.freeradbiomed.2022.01.001. Epub 2022 Jan 6.